September 13, 2018
Project Team Member Application – DS-8201a
Applicants, please submit the form to the NRG protocol development office by COB Wednesday, September 26, 2018. NRG Oncology will submit the application to CTEP by the deadline of October 3, 2018.
August 27, 2018
Labor Day closures for Operations, SDMCs, Biospecimen Banks, Serum Bank, and McKesson's Clinical Research Services. Read more
August 23, 2018
Matthew F. Hudson, PhD, MPH, NRG Oncology Cancer
Care Delivery Research (CCDR) Vice Chair, has been appointed by the PatientCentered
Outcomes Research Institute (PCORI) as a member of its Advisory
Panel on Patient Engagement.
July 19, 2018
The Digital Health and Personal Connected Health Minisymposium was held at the NRG Oncology Seminannual Meeting on July 12th. This session reviewed the ins-and-outs of digital health and the technology that is currently being used to improve the way we deliver cancer care. The recording of this session is now available here.
June 25, 2018
4th of July closures for Operations, SDMCs, Biospecimen Banks, Serum Bank, and McKesson's Clinical Research Services. Read more
June 25, 2018
NRG Oncology’s GOG-0218 Trial Leads to FDA Approval of Chemotherapy with Bevacizumab for Women with Ovarian Cancer Following Initial Surgery
The U.S. Food and Drug Administration (FDA) recently approved the use of bevacizumab (Avastin®) in combination with carboplatin and paclitaxel followed by Avastin as a single agent, as a treatment for women with advanced stage III or IV ovarian, fallopian tube, or primary peritoneal cancer following initial surgical resection. The FDA approval stems from the results of the double blind, placebo-controlled, phase 3 NRG Oncology trial GOG-0218, which revealed the addition of bevacizumab improved progression-free survival (PFS) for women when compared to chemotherapy alone. GOG-0218 was conducted by the Gynecologic Oncology Group (GOG, now part of NRG Oncology) and sponsored by the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI) under its Cooperative Research and Development Agreement with Genentech, a member of the Roche Group, for bevacizumab. Read more
June 18, 2018
An Important Word from Quality Assurance About Protocol Amendments
In order to avoid problems at audit and at the time of patient enrollments, site staff must more closely monitor the NRG Oncology Weekly Broadcast for protocol amendments. Amendments are announced in the weekly (typically Monday) broadcast under the heading, Protocol Activity, or sometimes, they are announced during the week in a separate broadcast. Regardless, the location/website where the amendment is posted is included in the announcement. We understand some staff have problems receiving the e-mail broadcasts; so please spread the word that broadcasts are posted to the NRG Oncology website under the News tab and can be monitored from there.
May 21, 2018
Memorial Day closures for Operations, SDMCs, Biospecimen Banks, Serum Bank, and McKesson. Read more
May 7, 2018
Project Team Member Application – Rogaratinib
Applicants, please submit the form to the NRG protocol development office by COB Friday, May 18, 2018. NRG Oncology will submit the application to CTEP by the deadline of May 25, 2018.
April 4, 2018
Dr. Chakravarti Selected to Serve on NCI Advisory Board of Scientific Counselors
Arnab Chakravarti, MD of the Ohio State University and co-Chair of the NRG Oncology Brian Tumor Committee, was recently selected to serve a five-year term on the National Cancer Institute (NCI) Advisory Board of Scientific Counselors. In his new role, Dr. Chakravarti will be chairing the review of the NCI Radiation Oncology Program and of the NCI Neuro-Oncology Program in future years.
Dr. Chakravarti’s experience includes research regarding novel biomarkers and uncovering key molecular and genetic mechanisms of treatment resistance in cancer. His team was among the first to report that the dysregulation of PI3K/AKT signaling is associated with radiation resistance in glioblastomas. Read more
March 30, 2018
Dr. Felix Feng Selected as the New NRG
Oncology Genitourinary Cancer Committee Chair
NRG Oncology has appointed Felix Feng, MD of the University of California at San Francisco as Chair of its Genitourinary Cancer Committee. He will follow Howard M. Sandler, MD, MS, who dedicated twenty-one years of leadership and direction for the committee.
Dr. Feng, a nationally and internationally recognized expert in the care of patients with genitourinary malignancies, has helped to initiate several clinical trials which have been among the first to utilize genomic biomarkers to help personalize therapy for prostate cancer patients. He has built a comprehensive research program focused on translating laboratory findings to the clinic to help guide patient care. Read more
March 23, 2018
Drs. Bernard Fisher and Norman Wolmark receive Society of Surgical Oncology's 2018 Charles M. Balch, MD Distinguished Service Award. Read more
March 12, 2018
Project Team Member Application – Radium-223
Applicants, please submit the form to the NRG protocol development office by COB Thursday, March 22, 2018. NRG Oncology will submit the application to CTEP by the deadline of March 29, 2018.
March 7, 2018
NRG Oncology NCORP PI, Dr. Bruner, Appointed as NCI Global Health
Working Group Co-Chair
Deborah Watkins Bruner, RN, PhD, FAAN, NRG Oncology’s National Cancer Institute (NCI) National Community Oncology Research Program (NCORP) grant contact primary investigator (PI) and deputy group chair of the organization’s Scientific Publications Committee, was recently appointed as Co-chair of NCI’s Global Health Working Group. In her new role, Dr. Bruner will be reviewing the NCI global portfolio and providing recommendations for the allocation of NCI’s resources. Read more
February 19, 2018
NRG Oncology NCORP Pilot Projects
NRG Oncology NCORP is soliciting PILOT projects for applications focused on NRG NCORP Cancer Prevention and Control (CPC) priorities that will provide data that will directly lead to future Phase II-III CPC concepts. As put forward in our core grant, CPC priorities for funding are:
- Cancer prevention research aimed at identifying and evaluating interventions to reduce the risk and incidence of cancer
- Cancer control research aimed at reducing the incidence and co-morbidity of cancer and its treatment focused on the four symptomatic management themes: neurotoxicity, cardiotoxicity, lymphedema, and inflammation (including cancer-related fatigue)
- Survivorship and palliative care interventions aimed at reducing toxicity and symptom burden, and improving quality of life (QoL)
- Cancer disparity research, in collaboration with our Health Disparities Research (HDR) Program, focused on efforts to increase the participation of minorities and underserved populations in CPC studies
- Integral to these priorities, are the establishment of biospecimen repositories for molecular studies.
For full details read more
NRG Oncology NCORP is soliciting PILOT projects for applications focused on NRG NCORP Cancer Care Delivery Research priorities that will provide data that will directly lead to future CCDR concepts. As put forward in our core grant, CCDR priorities for funding are:
- Implementation of guideline-based care
- Patient-reported outcomes (PROs)
- Decision-making tools
- Patient navigation
- Survivorship and surveillance
For full details read more
February 14, 2018
NRG Oncology Appoints NCORP Investigator, Matthew Hudson, as Cancer Care
NRG Oncology recently appointed Matthew F.
Hudson, PhD, MPH as Co-Chair for the organization’s Cancer Care Delivery
Research (CCDR) Committee. He joins the present Co-Chair Debra
Ritzwoller in the leadership of this committee. Drs. Hudson and Ritzwoller
each represent a National Cancer Institute (NCI) Community Oncology
Research Program (NCORP) institution. Participating NCORP community
sites, like the ones Drs. Hudson and Ritzwoller represent, make cancer
research available to larger and more diverse patient populations. Dr.
Hudson’s addition to the leadership team may enhance NRG Oncology’s
capacity to evolve community-informed research protocols.
February 13, 2018
Aghajanian Appointed as NRG Oncology Gynecologic Cancer Committee Chair
Carol Aghajanian, MD of Memorial Sloan Kettering Cancer Center (MSK) in New York has been named Chair of NRG Oncology’s Gynecologic Cancer Committee. Dr. Aghajanian’s experience in gynecologic cancer research and her leadership at MSK and within the National Cancer Institute (NCI)’s National Clinical Trials Network (NCTN) will be invaluable to NRG Oncology as the organization pursues its mission of improving the lives of cancer patients through multi-institutional clinical and translational research. She follows the prior NRG Oncology Gynecologic Cancer Committee Chair, Robert S. Mannel, MD, who was elected as an NRG Oncology Group Chair in 2017. Read more
February 1, 2018
NRG Oncology Appoints Kati Stoermer for New Executive Director Role
NRG Oncology, one of the five funded network groups within the National
Cancer Institute (NCI)’s National Clinical Trials Network
(NCTN), has appointed Kati Stoermer as the organization’s
Executive Director. In this new role, Stoermer will be
providing oversight and management of the NRG Oncology
operational activities coordinated by staff located in
Philadelphia and Pittsburgh. She will also be coordinating
with the organization’s Statistical and Data Management
Center and the group’s Biospecimen Bank.